Hepatocellular Carcinoma
Conditions
Brief summary
To assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence.
Detailed description
Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Recurrence of HCC is still a great challenge and threat to the patients after resection surgery. Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. HCC patients who meet the eligibility criteria of this clinical trial will be administrated Anlotinib 12mg QD PO d1-14, 21 days per cycle. The disease free survival (DFS), overall survival (OS) and any adverse effect during the 8 cycles of Anlotinib treatment will be evaluated in order to assess the primary effects and safety of Anlotinib in HCC patients at high risk of post surgery recurrence.
Interventions
DRUGAnlotinib Hydrochloride
Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
Sponsors
Shulan (Hangzhou) Hospital
West China Hospital
Huashan Hospital
Third Affiliated Hospital, Sun Yat-Sen University
The First Affiliated Hospital of Zhengzhou University
The First Hospital of Jilin University
Tianjin First Central Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* No allergic history of Anlotinib * 18-75 years * No history of severe arrhythmia or heart failure * No history of severe ventilation dysfunction or severe pulmonary infection * No acute or chronic renal failure, creatinine clearance \> 40 mL/min * Liver function is normal: child-pugh grade A or grade B (≤7 points), total bilirubin ≤ 3.0 mg/dL, albumin ≥ 28 g/L, AST, ALT, ALP≤ 5 times of the upper limit of normal value * Blood test: the absolute neutrophil count ≥ 1.5×10\^9 /L, Hb ≥ 8.5 g/L, PLT ≥ 75×10\^9 /L (without blood transfusions and drug therapy 14 days before the screening) * Blood coagulation function: INR≤2.3 * ECOG: 0-2 * Pathology: hepatocellular carcinoma * Satisfy any of the following: A. portal vein, hepatic vein or bile duct carcinoma thrombus B. microvascular invasion (MVI) grade II (\> 5 MVI, or MVI occurs in the area more than 1 cm from the tumor) C. tumor number ≥ 3 D. preoperative rupture of tumor or tumor invasion adjacent organs * Patients participate in the study voluntarily and sign informed consent
Exclusion criteria
* Pregnant or lactating women * Patients who have had or are currently complicated with other malignant tumors * Recurrent hepatocellular carcinoma * Patients who participated in other clinical trials within 1 month * Patients with mental illness * Patients treated with targeted drugs, immunotherapy (such as PD1 antibody), FOLFOX systemic chemotherapy or huaier granules after surgery * Urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease free survival | From randomization to recurrence of HCC or death (up to 1year) | The period from resection surgery to recurrence of HCC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse effect | Up to 1year | Any adverse effects occur during the use of anlotinib |
| Overall survival | 1 year | The survival rate in a year |
Countries
China
Outcome results
None listed